Ursula A. Matulonis, MD, Discusses Rationale for Assessing Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, spoke with CancerNetwork® about the rationale for assessing mirvetuximab soravtansine (IMGN853) in patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

In particular, she highlights the population of the phase 3 SORAYA trial (NCT04296890), which included patients who had previously received bevacizumab (Avastin). She also stated that those with high-grade serous ovarian cancer are likely to have high levels of FRα, making them a potential good fit for treatment with mirvetuximab soravtansine.

Transcript:

This is a phase 3 study for patients with FRα-high, or FRα-positive, platinum-resistant ovarian cancer. Patients were required to have prior bevacizumab and they could [have received] up to 3 lines of prior treatment, and they could also have received PARP inhibitors. The rationale [behind this trial is rooted in the fact that] high-grade serous ovarian cancer is a cancer that has high levels of FRα. In high-grade serous [disease], high levels are present in about 40% of patients’ cancers. The rationale has been that in pooled trials, we’ve seen response rates that are near 30% in a very similarly designed and selected patient populations as in SORAYA.

Reference

Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.